6-氨基己酸己基酯 | 372-52-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 6-氨基己酸己基酯
• 中文别名: 7-[[4,6-二[4-(2-氨基乙基)-1-哌嗪基]-1,3,5-三嗪-2-基]氨基]-4-羟基-3-[[p-(苯偶氮基)苯基]偶氮]萘-2-磺基酸,甲酸酯,盐酸,甲磺化
• 英文名称: 6-amino-n-caproic acid n-hexyl ester
• 英文别名: hexyl 6-aminohexanoate；ε-Aminocapronsaeure-hexylester；epsilon-Aminocaproic acid hexyl ester
• CAS: 372-52-1
• 化学式: C₁₂H₂₅NO₂
• 分子量: 215.336
• InChiKey: DJMXYHYLDLVMCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  6-氨基己酸己基酯 在 sodium hydroxide 、 sodium cyanoborohydride 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 49.0h， 生成 6-(n-propylamino)hexanoic acid
  参考文献：
  名称：

  A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis

  摘要：

  A new amine-oxide hapten was employed as an antigen, producing seven monoclonal antibodies (mAbs) from a panel of 20 that catalyzed paraoxon hydrolysis. The current hapten design differs from that previously described in that the molecule is inherently more flexible than its constrained predecessor. One of the seven antibody catalysts, mAb 1H9, showed the highest activity and was selected for detailed study. At pH = 8.77, the catalytic hydrolysis of paraoxon by mAb 1H9 followed Michaelis-Menten kinetics affording a k(cat) = 3.73 x 10(-4) min(-1) and a K-m,= 1.12 mM with a rate acceleration k(cat)/k(uncat) = 56. The hapten was found to be a competitive inhibitor of antibody-catalyzed paraoxon hydrolysis with a K-i,= 0.54 mM. A comparison of both the number and proficiency of antibody catalysts obtained when utilizing a flexible versus constrained hapten indicates that, for paraoxon hydrolysis, constrained haptens elicit superior catalysts, suggesting that further development should begin with the use of constrained haptens in producing more proficient antibody catalysts for paraoxon hydrolysis. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00026-7
• 作为产物：
  描述：

  6-氨基己酸盐酸盐 在 氯化亚砜 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 0.83h， 生成 6-氨基己酸己基酯
  参考文献：
  名称：

  Hrabalek; Dolezal; Roman, Pharmazie, 1994, vol. 49, # 5, p. 325 - 328

  摘要：

  DOI：

文献信息

• Hepatocyte growth factor HGF converting protease and gene encoding said protease
  申请人：Mitsubishi Chemical Corporation

  公开号：EP0596524A2

  公开（公告）日：1994-05-11

  A gene encoding a protease derived from human serum and having an activity to convert single-chain hepatocyte growth factor (HGF) into active two-chain HGF and a method of producing the protease by the use of said gene are provided. A method of producing a precursor protein of said protease is also provided.

  本研究提供了一种编码从人类血清中提取的蛋白酶的基因，该蛋白酶具有将单链肝细胞生长因子（HGF）转化为活性双链 HGF 的活性，还提供了一种利用上述基因生产蛋白酶的方法。还提供了一种生产所述蛋白酶前体蛋白的方法。
• TOCHACEK, JIRI
  作者：TOCHACEK, JIRI

  DOI：——

  日期：——
• OMEGA-AMINO ACID DERIVATIVES, PROCESSES OF THEIR PREPARATION AND THEIR USE
  申请人：Biochemie S.R.O.

  公开号：EP0973710A2

  公开（公告）日：2000-01-26
• [EN] OMEGA-AMINO ACID DERIVATIVES, PROCESSES OF THEIR PREPARATION AND THEIR USE<br/>[FR] DERIVES D'ACIDES OMEGA-AMINES, PROCEDES DE PREPARATION ET UTILISATION
  申请人：——

  公开号：WO1998045233A2

  公开（公告）日：1998-10-15

  [EN] The invention relates to omega -amino acid derivatives of general formula (I), wherein R<1> is H or CH3, X is H or NR<2>R<3>, wherein R<2> is H, CH3, COH or COCH3 and R<3> is H, CH3 or COO<->Z, wherein Z is R<2>R<3> NH<+>CHR<1>(CH2)nCOO(CH2)mCH2Y; Y is H, CH3 or NHR<4>, wherein R<4> is COO<->NH3<+>CH2(CH2)mOOC(CH2)nCH3, the meaning of group (CH2)m being selected from alkyls, secondary alkyls, monocycloalkyls, bicycloalkyls and tricycloalkyls having from 4 to 15 carbon atoms and n having a value of from 3 to 14. omega -Amino acid derivatives of the invention are prepared by reacting a primary or secondary or monocyclic or bicyclic or tricyclic alcohol with the reaction product of an amino acid or an N-substituted amino acid with thionyl chloride, whereafter the amino group, which has been released by an amine, reacts with carbon dioxide providing a derivative of carbamic acid, or by directly reacting a primary or secondary or monocyclic or bicyclic or tricyclic alcohol with an N-substituted amino acid in the presence of a condensing agent giving the corresponding ester of the N-substituted amino acid. Thus produced compounds of formula (I) can be used as transdermal penetration enhancers. Incorporation of from 0.1 w/w percent to 5.0 w/w percent of a compound of the invention as a transdermal penetration enhancer in the vehicle of a topically applied pharmaceutical or cosmetic composition enhances transdermal penetration of pharmaceutical agents through the human or animal skin. Included further are transdermal penetration enhancers consisting of at least one compound of formula (I).
  [FR] L'invention concerne des dérivés d'acides omega -aminés de formule générale (I), dans laquelle R<1> désigne H ou CH3, X désigne H ou NR<2>R<3>, où R<2> désigne H, CH3, COH ou COCH3 et R<3> désigne H, CH3 ou COO<->Z, où Z désigne R<2>R<3> NH<+>CHR<1>(CH2)nCOO(CH2)mCH2Y; Y désigne H, CH3 ou NHR<4>, où R<4> désigne COO<->NH3<+>CH2(CH2)mOOC(CH2)n CH3, le groupe (CH2)m étant sélectionné parmi les alkyles, alkyles secondaires, monocycloalkyles, bicycloalkyles et tricycloalkyles présentant entre 4 et 15 atomes de carbone et dont n correspond à une valeur comprise entre 3 et 14. On prépare les dérivés d'acides omega -aminés faisant l'objet de cette invention en faisant réagir un alcool monocyclique, bicyclique ou tricyclique primaire ou secondaire avec le produit de réaction d'un acide aminé ou d'un acide aminé N substitué avec du chlorure de thionyle, après quoi le groupe aminé, qui a été libéré par une amine, réagit avec du dioxyde de carbone ce qui produit un dérivé d'acide carbamique, ou en faisant réagir directement un alcool monocyclique, bicyclique ou tricyclique primaire ou secondaire avec un acide aminé N substitué en présence d'un agent de condensation, ce qui produit l'ester correspondant de l'acide aminé N substitué. Les composés de formule (I) ainsi obtenus peuvent être utilisés comme activateurs de pénétration transdermique. L'introduction de 0,1 % (m/m) à 5,0 % (m/m) d'un composé selon l'invention, servant d'activateur de pénétration transdermique, dans le support d'une composition cosmétique ou pharmaceutique topique renforce la pénétration transdermique d'agents pharmaceutiques chez l'homme et l'animal. L'invention concerne en outre des activateurs de pénétration transdermique formés d'au moins un composé de formule (I).
• A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis
  作者：David A. Spivak、Timothy Z. Hoffman、Alisa H. Moore、Matthew J. Taylor、Kim D. Janda

  DOI：10.1016/s0968-0896(99)00026-7

  日期：1999.6

  A new amine-oxide hapten was employed as an antigen, producing seven monoclonal antibodies (mAbs) from a panel of 20 that catalyzed paraoxon hydrolysis. The current hapten design differs from that previously described in that the molecule is inherently more flexible than its constrained predecessor. One of the seven antibody catalysts, mAb 1H9, showed the highest activity and was selected for detailed study. At pH = 8.77, the catalytic hydrolysis of paraoxon by mAb 1H9 followed Michaelis-Menten kinetics affording a k(cat) = 3.73 x 10(-4) min(-1) and a K-m,= 1.12 mM with a rate acceleration k(cat)/k(uncat) = 56. The hapten was found to be a competitive inhibitor of antibody-catalyzed paraoxon hydrolysis with a K-i,= 0.54 mM. A comparison of both the number and proficiency of antibody catalysts obtained when utilizing a flexible versus constrained hapten indicates that, for paraoxon hydrolysis, constrained haptens elicit superior catalysts, suggesting that further development should begin with the use of constrained haptens in producing more proficient antibody catalysts for paraoxon hydrolysis. (C) 1999 Elsevier Science Ltd. All rights reserved.